🔗 Share this article The Global Health Body Issues Warning Over Critical Scarcity of Obesity Injections Less than 10% of patients eligible to benefit from obesity jabs like Wegovy are able to get them, warns the WHO as it issues its first guidance on the drugs. Considering in excess of 1,000,000,000 individuals worldwide now obese, it is urging broader and more equitable availability to GLP-1 medication. Based on forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken. "The new guidance acknowledges that excess weight is a lifelong illness that can be treated with comprehensive and continuous support," remarked WHO director-general Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and supply-chain constraints are significant barriers to widespread access to the jabs that can aid individuals in losing significant body mass, says the agency. GLP-1 Therapy Supply Crisis Even under the current most favorable outlook, the production of GLP-1 therapies would only suffice for around 100 million people – under 10% of those who need them, according to the health organization. The advice urges nations and manufacturers to expand availability, via approaches like voluntary licensing. The intellectual property rights on a key compound – the core component of a leading brand – is due to expire in multiple nations in 2026. How Obesity Injections Work These medications replicate a body's own hormone to slow digestion, reduce hunger and boost satiety so individuals consume fewer calories. Individuals commonly see weight reduction in the initial weeks of commencing the weekly injections. Evidence suggests patients may regain a significant portion after a year of discontinuing the drug, when their usual food cravings resume. To be carrying excess weight raises your likelihood for developing health problems, such as diabetes, heart disease, stroke, and some cancers. Excess weight concerns individuals in all nations and was responsible for over three and a half million deaths worldwide in 2024, per the health agency.
Less than 10% of patients eligible to benefit from obesity jabs like Wegovy are able to get them, warns the WHO as it issues its first guidance on the drugs. Considering in excess of 1,000,000,000 individuals worldwide now obese, it is urging broader and more equitable availability to GLP-1 medication. Based on forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken. "The new guidance acknowledges that excess weight is a lifelong illness that can be treated with comprehensive and continuous support," remarked WHO director-general Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and supply-chain constraints are significant barriers to widespread access to the jabs that can aid individuals in losing significant body mass, says the agency. GLP-1 Therapy Supply Crisis Even under the current most favorable outlook, the production of GLP-1 therapies would only suffice for around 100 million people – under 10% of those who need them, according to the health organization. The advice urges nations and manufacturers to expand availability, via approaches like voluntary licensing. The intellectual property rights on a key compound – the core component of a leading brand – is due to expire in multiple nations in 2026. How Obesity Injections Work These medications replicate a body's own hormone to slow digestion, reduce hunger and boost satiety so individuals consume fewer calories. Individuals commonly see weight reduction in the initial weeks of commencing the weekly injections. Evidence suggests patients may regain a significant portion after a year of discontinuing the drug, when their usual food cravings resume. To be carrying excess weight raises your likelihood for developing health problems, such as diabetes, heart disease, stroke, and some cancers. Excess weight concerns individuals in all nations and was responsible for over three and a half million deaths worldwide in 2024, per the health agency.